Characterization of tau in cerebrospinal fluid using mass spectrometry

被引:63
作者
Portelius, Erik [1 ]
Hansson, Sara F. [1 ]
Tran, Ai Jun [1 ]
Zetterberg, Henrik [1 ]
Grognet, Pierre [2 ]
Vanmechelen, Eugeen [2 ]
Hoglund, Kina [3 ]
Brinkmahn, Gunnar [1 ]
Westman-Brinkmalm, Ann [1 ]
Nordhoff, Eckhard [4 ]
Blennow, Kai [1 ]
Gobom, Johan [1 ]
机构
[1] Univ Gothenburg, Sahlgrens Univ Hosp, Dept Neurosci & Physiol, Clin Neurochem Lab, S-43180 Molndal, Sweden
[2] Innogenet, Ghent, Belgium
[3] AstraZeneca CNS Pain, Dept Dis Biol, SE-15185 Sodertalje, Sweden
[4] Max Planck Inst Mol Genet, D-14195 Berlin, Germany
关键词
Alzheimer's disease; immunoprecipitation; MALDI-TOF MS; cerebrospinal fluid; tau; LC-MS/MS;
D O I
10.1021/pr7008669
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The neurodegenerative disorder Alzheimer's disease (AD) is the most common cause of dementia in the elderly. The presence of neurofibrillary tangles, consisting of hyperphosphorylated tau protein, is one of the major neuropathologic characteristics of the disease, making this protein an attractive biomarker for AD and a possible target for therapy. Here, we describe an optimized immunoprecipitation mass spectrometry method that enables, for the first time, detailed characterization of tau in human cerebrospinal fluid. The identities of putative tau fragments were confirmed using nanoflow liquid chromatography and tandem mass spectrometry. Nineteen tryptic fragments of tau were detected, of which 16 are found in all tau isoforms while 3 represented unique tau isoforms. These results pave the way for clinical CSF studies on the tauopathies.
引用
收藏
页码:2114 / 2120
页数:7
相关论文
共 22 条
[1]   Tau-mediated neurodegeneration in Alzheimer's disease and related disorders [J].
Ballatore, Carlo ;
Lee, Virginia M. -Y. ;
Trojanowski, John Q. .
NATURE REVIEWS NEUROSCIENCE, 2007, 8 (09) :663-672
[2]  
Blennow K, 2005, INT J MOL MED, V16, P1147
[3]   CSF markers for incipient Alzheimer's disease [J].
Blennow, K ;
Hampel, H .
LANCET NEUROLOGY, 2003, 2 (10) :605-613
[4]   tau protein in cerebrospinal fluid - A biochemical marker for axonal degeneration in Alzheimer disease? [J].
Blennow, K ;
Wallin, A ;
Agren, H ;
Spenger, C ;
Siegfried, J ;
Vanmechelen, E .
MOLECULAR AND CHEMICAL NEUROPATHOLOGY, 1995, 26 (03) :231-245
[5]   Alzheimer's disease [J].
Blennow, Kaj ;
de Leon, Mony J. ;
Zetterberg, Henrik .
LANCET, 2006, 368 (9533) :387-403
[6]   α-cyano-4-hydroxycinnamic acid affinity sample preparation.: A protocol for MALDI-MS peptide analysis in proteomics [J].
Gobom, J ;
Schuerenberg, M ;
Mueller, M ;
Theiss, D ;
Lehrach, H ;
Nordhoff, E .
ANALYTICAL CHEMISTRY, 2001, 73 (03) :434-438
[7]   Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease -: A comparative cerebrospinal fluid study [J].
Hampel, H ;
Buerger, K ;
Zinkowski, R ;
Teipel, SJ ;
Goernitz, A ;
Andreasen, N ;
Sjoegren, M ;
DeBernardis, J ;
Kerkman, D ;
Ishiguro, K ;
Ohno, H ;
Vanmechelen, E ;
Vanderstichele, H ;
McCulloch, C ;
Möller, HJ ;
Davies, P ;
Blennow, K .
ARCHIVES OF GENERAL PSYCHIATRY, 2004, 61 (01) :95-102
[8]   Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis [J].
Hanger, Diane P. ;
Byers, Helen L. ;
Wray, Selina ;
Leung, Kit-Yi ;
Saxton, Malcolm J. ;
Seereeram, Anjan ;
Reynolds, C. Hugh ;
Ward, Malcolm A. ;
Anderton, Brian H. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (32) :23645-23654
[9]   Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study [J].
Hansson, O ;
Zetterberg, H ;
Buchhave, P ;
Londos, E ;
Blennow, K ;
Minthon, L .
LANCET NEUROLOGY, 2006, 5 (03) :228-234
[10]   Tauopathies [J].
Hernandez, F. ;
Avila, J. .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2007, 64 (17) :2219-2233